Highlights from ASCO 2025: BRAF-mutant colorectal cancer (CRC)

Prof. Dr Dominik Modest studied medicine at the Charité in Berlin, Germany and at the University of Bern, Switzerland. Currently, after 10 years at the LMU in Munich, Germany, he is a physician at the Charité Universitaetsmedizin Berlin, Germany. His research activities focus on metastatic colorectal cancer and include the concept and coordination of trials for the FIRE study group and the Arbeitsgemeinschaft Internistische Onkologie (AIO). Prof. Dr Modest also coordinates the translational research components of these trials, aiming to identify prognostic and predictive biomarkers of metastatic colorectal cancer. His research has been published in several papers in scientific journals. In 2015, he received a postdoctoral qualification on factors for personalisation of metastatic colorectal cancer therapy and a full professorship in 2020.  Prof. Dr Modest is an active member of several national and international cancer associations and served as spokesman for the Young Medical Oncologists of the AIO until 2014.

Dr Sara Lonardi is Chief of the Oncology 1 Unit of Veneto Institute of Oncology (IOV) – IRCCS. She obtained her Medical Degree in 2000 and her Oncology specialization in 2004, both from the University of Padova. She has been actively interested in the care of gastrointestinal cancer patients since 1998, and in 2013 became chief of the GI Cancer Unit, being involved in several international and national clinical trials as Principal Investigator. She was also Chief of Phase I Clinical Trial Unit at IOV-IRCCS and pro tempore Chief of the Oncology 3 Unit at IOV-IRCCS. She has published more than 200 scientific articles in peer-reviewed journals dealing with gastrointestinal cancers clinical and translational research. She is an active member of Associazione Italiana di Oncologia Medica-AIOM, European Society of Medical Oncology-ESMO and American Society of Medical Oncology-ASCO, and member of the Steering Committee of the ACCENT DataBase.